RMM Directory - medicines starting with E

About Effentora - Information for Healthcare Professionals

For Healthcare Professionals

About Effentora - Information for Patents and Caregivers

Effentora Treatment Diary

Elidel Educational brochure for HCPs

Important information on the appropriate use of Elidel for HCPs

For Healthcare Professionals

Eliquis (apixaban) Healthcare Professional Risk Minimisation Material Website

This website is for healthcare professionals (HCPs) and is based on the paper and electronic version of the Eliquis (apixaban) Prescriber Guide. The website contains information for HCPs to be aware of before prescribing apixaban and in particular is aimed at increasing awareness about the potential risk of bleeding with apixaban. The website includes information on increased bleeding risks with apixaban, guidance on the use of apixaban in patients undergoing surgery and invasive procedures, therapy management, management of overdose and haemorrhage. The site can be viewed using Firefox, Google Chrome or recent versions of Internet Explorer.

For Healthcare Professionals

Eliquis (apixaban) Patient Alert Card

Patients prescribed Eliquis (apixaban) will receive a Patient Alert Card in the medication pack with the package leaflet. Please ensure you have read and understood the information in the card because it contains important safety information including the importance of taking apixaban regularly as instructed by the doctor, the main signs and symptoms of bleeding, and when to seek medical attention. Please carry the Patient Alert Card with you at all times and show it to every healthcare professional including pharmacists. Editorial updates were recently made to the card and the latest version of the card is dated January 2021. If you have lost the copy of the Patient Alert Card that is included in the medication pack, or it is damaged, please contact BMS Medical Information for a replacement copy (telephone: 0800 731 1736; e-mail: [email protected]).

Eliquis (apixaban) Prescriber Guide

This risk minimisation material is for Eliquis for all indications. Please ensure that you are familiar with this material before prescribing Eliquis as it contains important safety information on the potential risk of bleeding during treatment with Eliquis and provides guidance on how to manage that risk. Updates made to the Prescriber Guide in in May 2021 reflect changes to the Summary of Product Characteristics (SPC) for apixaban 2.5 mg and 5 mg tablets on ‘Patients with active cancer’. Other editorial changes were made including updates to the presentation of the Prescriber Guide. If you would like to obtain hard copies of the Eliquis Prescriber Guide and/or Patient Alert Card and/or SPCs, please contact Bristol-Myers Squibb Medical Information (telephone: 0800 731 1736; Email: [email protected]) with your specific request. Risk minimisation materials can only be delivered to UK registered healthcare premises.

For Healthcare Professionals

CHCs - Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers

For Healthcare Professionals

CHCs - Q&A on Important Info for Women

Combined hormonal contraceptives: Q&As about the important information for women.

CHCs - Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

Elvanse - Chart for ongoing monitoring of lisdexamfetamine therapy - HCP - Nov2017

For Healthcare Professionals

Elvanse - Checklist 1: lisdexamfetamine checklist before prescribing - HCP - Nov2017

For Healthcare Professionals

Elvanse - Checklist 2: checklist for ongoing monitoring of lisdexamfetamine therapy - HCP - Nov2017

For Healthcare Professionals

Elvanse - potential for non-medical use & diversion of prescription stimulant medications - Pt - Nov2017

Elvanse Adult - Chart for ongoing monitoring of lisdexamfetamine therapy - HCP - Dec2016

For Healthcare Professionals

Elvanse Adult - Checklist 1: lisdexamfetamine dimesylate checklist before prescribing - HCP - Dec2016

For Healthcare Professionals

Elvanse Adult - Checklist 2: checklist for ongoing monitoring of lisdexamfetamine dimesylate therapy - HCP - Dec2016

For Healthcare Professionals

Elvanse Adult - potential for non-medical use & diversion of prescription stimulant medications - Pt - Dec2016

Emerade Expiry Reminder

Enter your pen expiry dates below and we will remind you to re-order your prescription 30 days before via email. Alternatively you can download a calendar reminder to save in your phone or computer calendar.

How to use Emerade instruction video

Demonstration video to show you how to use your Emerade autoinjector pen.

Emerres 1.5mg - Patient Advice Leaflet

Patient leaflet explaining about what you may need to do and who you should contact if taking various other medication.

Emerres Una - Patient Advice Leaflet

Includes information for women that are taking other medicines and what you may need to do and who you may need to talk to.

Emerres Una - Patient Questionnaire Checklist

The following list of questions is designed to support you in determining whether Emerres Una is a suitable choice of emergency contraceptive for an individual patient following unprotected sexual intercourse or contraceptive failure.

For Healthcare Professionals

Emtricitabine/Tenofovir disoproxil Dr. Reddy's 200 mg/245 mg Film-Coated Tablets

Renal and bone effects risk minimisation material: Tenofovir disoproxil for children and adolescents with HIV-1

For Healthcare Professionals

Checklist for Prescribers v2 Tenofovir PrEP

Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP) Complete checklist at each visit and file in individuals medical record.

For Healthcare Professionals

Important Information about Emtricitabine/Tenofovir Disoproxil To Reduce The Risk Of Getting Human Immunodeficiency Virus (HIV) Infection

Information for individuals who have been prescribed emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

Important Safety Information for prescribers v2 Tenofovir PrEP

Emtricitabine/ tenofovir disoproxil is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and on men and women in heterosexual serodiscordant couples.

For Healthcare Professionals

Reminder Card v2 Tenofovir PrEP

You have been prescribed emtricitabine/ tenofovir disoproxil for PrEP (pre-exposure prophylaxis) to help reduce the risk of getting HIV-1 infection. For this medicine to work effectively it is important that you don’t miss doses. The recommended dose is one emtricitabine/ tenofovir disoproxil tablet each day. Take emtricitabine/ tenofovir disoproxil exactly as your doctor has told you.

Checklist for Prescribers

Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

For Healthcare Professionals

Important Information about Emticitabine/Tenofovir Disproxil

Information for individuals who have been prescribed emtricitabine/ tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

For Healthcare Professionals

Important Safety Information for Prescribers

For Prescribers About emtricitabine/ tenofovir disoproxil for a Pre-Exposure Prophylaxis (PrEP) Indication

For Healthcare Professionals

Reminder Card

EMTRICITABINE/ TENOFOVIR DISOPROXIL FOR PrEP REMINDER CARD

For Healthcare Professionals

CHECKLIST FOR PRESCRIBERS EMTRICITABINE/TENOFOVIR

Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP) Complete checklist at each visit and file in individual’s medical record.

For Healthcare Professionals

Important safety information for individuals to reduce the risk of getting HIV

This guide is intended for information only and should complement (not replace) the patient information leaflet supplied with your medicine. For a full list of side effects and other important information, please refer to the patient information leaflet provided in the box containing your medicine. Ask your healthcare provider if you have any questions.

For Healthcare Professionals

important safety information for prescribers v2 Tenofovir PrEP

Emtricitabine/ tenofovir disoproxil is indicated in combination with safer sex practices for preexposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and on men and women in heterosexual serodiscordant couples.

For Healthcare Professionals

Reminder card v2 Tenofovir PrEP

You have been prescribed emtricitabine/ tenofovir disoproxil for PrEP (pre-exposure prophylaxis) to help reduce the risk of getting HIV-1 infection. For this medicine to work effectively it is important that you don’t miss doses. The recommended dose is one emtricitabine/ tenofovir disoproxil tablet each day. Take emtricitabine/ tenofovir disoproxil exactly as your doctor has told you.

For Healthcare Professionals

RENAL AND BONE EFFECTS RISK MINIMISATION MATERIAL:TENOFOVIR DISOPROXIL FOR CHILDREN AND ADOLESCENTS WITH HIV-1

Submission of Risk Minimisation Materials (coordinated by BGMA) to agency – minimising the risks of renal and bone effects for children and adolescents with HIV

Checklist for prescribers of Emtricitabine/Tenofovir

Checklist for the initiation of Emtricitabine/Tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

For Healthcare Professionals

Important information about Emtricitabine/Tenofovir to reduce the risk of getting HIV infection

Information for individuals who have been prescribed Emtricitabine/Tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

Important safety information for prescribers of Emtricitabine/Tenofovir

Important safety information for prescribers of Emtricitabine/Tenofovir disoproxil for a Pre-Exposure Prophylaxis (PrEP) indication

For Healthcare Professionals

Patient Reminder Card

Patient Reminder Card: Emtricitabine/Tenofovir disoproxil for PrEP indication

Renal and bone effects risk minimisation material: Tenofovir disoproxil for children and adolescents with HIV-1

This brochure provides important advice on the management of potential renal and bone effects of tenofovir disoproxil in HIV-1 infected children and adolescents aged 2 to <18 years, and on the dosing recommendations for tenofovir disoproxil in this population.

For Healthcare Professionals

Checklist for Prescribers v2 Tenofovir PrEP

For Healthcare Professionals

Important safety information for individuals using PrEP v2

For Healthcare Professionals

Important safety information for prescribers v2 Tenofovir PrEP

For Healthcare Professionals

Reminder card v2 Tenofovir PrEP

For Healthcare Professionals

Tenofovir HBV indications materials for children and adolescents

For Healthcare Professionals

Tenofovir HIV indications materials for children and adolescents

For Healthcare Professionals

Emtricitabine/Tenofovir disoproxil Checklist for Prescribers

Emtricitabine/Tenofovir disoproxil Checklist for Prescribers PrEP

For Healthcare Professionals

Emtricitabine/Tenofovir Disoproxil Patient Brochure

Patient Brochure for Emtricitabine/Tenofovir disoproxil for PrEP (pre-exposure prophylaxis)

Emtricitabine/Tenofovir Disoproxil Prescriber's Brochure

Important Safety Information for Prescribers About Emtricitabine/Tenofovir Disoproxil for a Pre-exposure Prophylaxis (PrEP) Indication

For Healthcare Professionals

Emtricitabine/Tenofovir HIV Paediactrics Brochure

Emtricitabine/Tenofovir HIV Paediactrics Brochure advice for HCPs

For Healthcare Professionals

Patient Reminder Card for Emtricitabine/Tenofovir Disoproxil

Patient Reminder Card for Emtricitabine/Tenofovir disoproxil for PrEP (pre-exposure prophylaxis).

HBV Indications - children and adolescents v4

This material provides important information and advice on the management of potential renal and bone effects of the use of tenofovir disoproxil in adolescents with chronic hepatitis B aged 12 to <18 years.

HIV Indications - children and adolescents

This material provides important information and advice on the management of potential renal and bone effects of the use of tenofovir disoproxil in adolescents infected with HIV-1 aged 2 to <18 years.

PrEP - Checklist for Prescribers v2

Checklist to be completed at each visit and filed in individuals medical records.

PrEP - Important safety information for individuals using v2

This guide is intended for information only to support the patient information leaflet, to provide the patient with additional information to reduce the risk of getting Human Immunodeficiency Virus (HIV) Infection.

PrEP - Important safety information for prescribers v2

This guide is to give the prescriber important safety information on Emtricitabine/Tenofovir to patients to reduce the risk of sexually acquired HIV-1 infections.

PrEP - Reminder card v2

This card is for each patient prescribed Emtricitabine/Tenofovir as a reminder to take the tablet each day.

Renal and Bone effects Risk Minimisation Material: Tenofovir Disoproxil for Children and Adolescents with HIV-1

HIV-1 Renal & bone effects education brochure - children and adolescent

For Healthcare Professionals

Enbrel Patient Alert Card

Enbrel Patient Card

HCP Guide for Prevention of Product Confusion Medication Errors

This HCP guide is a condition of the Marketing Authorisation for Enhertu. It serves to minimise the important potential risk of medication error in addition to the SmPC. HCPs should read it before prescribing and administering Enhertu (trastuzumab deruxtecan). Risk of confusion between Enhertu (trastuzumab deruxtecan) and other trastuzumab-containing products including Kadcyla (trastuzumab emtansine).

For Healthcare Professionals

HCP Guide: Important Safety Information on ILD/Pneumonitis with treatment of Enhertu

This HCP guide is: - provided for HCPs to read before prescribing and administering Enhertu - an important tool to ensure the early recognition and diagnosis of ILD/pneumonitis, to allow prompt and appropriate treatment and minimise serious outcomes - a reminder to distribute a Patient Card to any patient receiving Enhertu treatment for the first time or if asked for a new copy

For Healthcare Professionals

Patient Card: Enhertu

- This Patient Card has been provided to you because your doctor has prescribed you Enhertu. - This Patient Card helps you to identify symptoms of lung problems that you may experience with Enhertu. - Read this information before you start receiving Enhertu and before each infusion. - You should keep this card with you at all times and show it to any doctor you consult (for example if your regular doctor is unavailable or if you are travelling).

Entyvio (vedolizumab) HCP Educational Brochure

Information leaflet for HCPs Administering Entyvio

For Healthcare Professionals

Entyvio (vedolizumab) HCP Educational Brochure

Information leaflet for HCPs Administering Entyvio

For Healthcare Professionals

Entyvio (vedolizumab) Patient Alert Card

To be provided to patients receiving treatment with Entyvio by a HCP

Entyvio (vedolizumab) Patient Alert Card

To be provided to patients receiving treatment with Entyvio by a HCP

Envarsus – prolonged-release tacrolimus tablets

Educational materials for the healthcare professional (doctor or pharmacist) Please read the full Summary of Product Characteristics before prescribing Envarsus

For Healthcare Professionals

Envarsus Patient Card

Envarsus Prolonged-release tacrolimus tablets Patient Card

For Healthcare Professionals

Valproate- “White Box” Warning Labels

FOR DISPENSARY USE ONLY Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

For Healthcare Professionals

Valproate Annual Risk Acknowledgement Form

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

Valproate- Healthcare professionals (HCPs) Guide Pregnancy prevention programme

Educational material for Healthcare Professionals (HCPs) about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

For Healthcare Professionals

Valproate- Patient Card-Contraception and Pregnancy Prevention

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Valproate- Patient Guide- Pregnancy prevention programme

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Valproate- Poster- Dispensary- Pregnancy Prevention Programme

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

For Healthcare Professionals

EpiPen® Carry Card

Carry Card for EpiPen® patients

EpiPen® Expiry Alert Service

Expiry Alert Service using text or email for EpiPen® patients

EpiPen® Trainer Pen Order Form

Trainer Pen order form

EpiPen® Travel Certificate

Travel Certificate for those carrying EpiPen®

Guide to Using Your EpiPen® & Trainer Pen

Guide to Using Your EpiPen® & Trainer Pen leaflet

HCP Prescription Checklist for EpiPen and EpiPen Jr

Checklist for EpiPen and EpiPen Jr

For Healthcare Professionals

HCP Booklet - valproate use in female patients

Healthcare Professional (HCP) educational material, Pregnancy Prevention Programme

For Healthcare Professionals

Patient Card - valproate use in female patients

Patient Card for valproate in female patients - Contraception and Pregnancy Prevention

Patient Guide - valproate use in female patients

Patient Guide booklet for valproate in female patients - educational material, Pregnancy Prevention Programme

Valproate - Annual Risk Acknowledgement Form

Checklist for prescribers related to valproate use in female patients

For Healthcare Professionals

Valproate - Poster- Dispensary - Pregnancy Prevention Programme

Pharmacy poster reminding that valproate must be prescribed and dispensed according to the Valproate Pregnancy Prevention Programme.

For Healthcare Professionals

Valproate - White Box Warning Labels

Warning labels for box

For Healthcare Professionals

Valproate - “White Box” Warning Labels

FOR DISPENSARY USE ONLY Warning labels with valproate pregnancy pictogram for pharmacies to use with white box dispensing of these products. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Valproate - Annual Risk Acknowledgement Form

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

Valproate - Healthcare professionals (HCPs) Guide - Pregnancy Prevention Programme

Educational material for Healthcare Professionals (HCPs) about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

For Healthcare Professionals

Valproate - Patient Card - Contraception and Pregnancy Prevention

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Valproate - Patient Guide - Pregnancy Prevention Programme

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Valproate - Poster - Dispensary - Pregnancy Prevention Programme

FOR DISPENSARY USE ONLY Dispensary A4 Poster for pharmacies with key information about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

For Healthcare Professionals

Equasym - ADHD physicians guide to prescribing - July2021

For Healthcare Professionals

Equasym - Chart for ongoing monitoring during methylphenidate treatment - HCP - July2021

For Healthcare Professionals

Equasym - Checklist 1: checklist before prescribing - HCP - July2021

For Healthcare Professionals